Influenza Clinical Trial
Official title:
Multicenter, Double-blind, Randomized, Parallel Group Study to Evaluate the Immunogenicity, Reactogenicity and Safety of the Grippol® Quadrivalent Vaccine in Children Aged 6 Months to 5 Years (Inclusive)
Verified date | November 2023 |
Source | NPO Petrovax |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this clinical study is to prove the no less immunogenicity of the Grippol Quadrivalent vaccine compared to the Grippol plus vaccine in children aged 6 months to 5 years (inclusive) for three identical strains of the compared vaccines in terms of the "proportion of vaccinated with seroconversion in paired sera of the hemagglutination inhibition reaction obtained before and after vaccination".
Status | Completed |
Enrollment | 824 |
Est. completion date | October 9, 2023 |
Est. primary completion date | June 15, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 6 Months to 5 Years |
Eligibility | Inclusion Criteria: 1. Male and female children aged 6 months to 5 years inclusive at the time of vaccination. 2. Availability of Informed consent to participate in the study, signed by one of the parents. 3. The diagnosis is "healthy", established according to standard clinical, laboratory and instrumental methods of examination carried out at screening, according to the assessment of the researcher, as well as anamnesis data (absence of acute and chronic diseases of the respiratory, cardiovascular, nervous systems, dysfunction liver or kidneys). 4. Negative result of a rapid test for SARS-CoV-2 antigen at screening. 5. For children aged 6 to 11 months inclusive: children born at gestational age =37 weeks weighing =2.5 kg. 6. Parental consent to cooperate in good faith with the investigator and center staff, attend scheduled visits, complete the self-monitoring diary, and follow the protocol. Exclusion Criteria: 1. Vaccination with any influenza vaccine within the previous 6 months. Vaccination with other vaccines, according to the national vaccination schedule, is allowed no later than 30 days before the introduction of the study vaccine, and no earlier than 30 days after the administration of the study vaccines. 2. Participation in a clinical trial of a vaccine, medicinal product, or medical device less than 30 days prior to screening. 3. Hypersensitivity to any of the components of the studied vaccines or severe post-vaccination complications to any vaccine in history. 4. The presence at the time of screening of acute infectious diseases of any localization, or the presence of a history of acute infectious and non-infectious diseases less than 14 days before screening. 5. Body temperature in the armpit =37.0°C at screening or before the introduction of the vaccine. 6. History of significant chronic diseases, such as malignant neoplasms or blood diseases, autoimmune diseases, insulin-dependent diabetes mellitus, chronic diseases of the lungs, liver or kidneys, cardiovascular, nervous systems, secondary, primary and induced immunodeficiency, HIV- infections, as well as other significant, according to the researcher, diseases. 7. A history of seizures or a progressive neurological disease. 8. History of Guillain-Barré syndrome (post-infectious demyelinating polyradiculoneuropathy of autoimmune etiology). 9. Use of antipyretics, including non-steroidal anti-inflammatory drugs less than 24 hours before screening and vaccination; antibacterial drugs of systemic action - less than 72 hours before screening and vaccination; anticoagulants - less than 3 weeks before screening and vaccination; immunoglobulins, blood products - less than 3 months before screening and vaccination; long-term use of systemic corticosteroids (prednisolone or equivalent for more than 2 consecutive weeks) - less than 3 months before vaccination screening. 10. Surgery performed less than 3 months prior to screening. 11. Children of research team members or research facility staff involved in this clinical trial. 12. Orphans, children left without parental care. 13. Any other medical or social condition that, in the opinion of the investigator, precludes the participation of the child in this study. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | State Autonomous Healthcare Institution of the Sverdlovsk Region "Children's City Clinical Hospital No. 11" | Ekaterinburg | |
Russian Federation | Federal State Budgetary Research Institution "Russian research center of surgery named after academician B.V. Petrovsky" | Moscow | |
Russian Federation | State Budgetary Healthcare Institution "Children's City Clinical Hospital No.9 named after G.N. Speransky of Moscow Healthcare Department" | Moscow | |
Russian Federation | State Budgetary Health Institution of the Perm Territory "City Children's Clinical Polyclinic No. 5 | Perm | |
Russian Federation | Limited Liability Company "Clinic USI 4D" | Pyatigorsk | |
Russian Federation | Federal State-Financed Institution Pediatric Research and Clinical Center for Infectious Diseases under the Federal Medical Biological Agency | Saint Petersburg | |
Russian Federation | Limited Liability Company " Energiia Zdoroviya" | Saint Petersburg | |
Russian Federation | Limited Liability Company Medical technology | Saint Petersburg | |
Russian Federation | Limited Liability Company PiterClinica | Saint Petersburg | |
Russian Federation | St. Petersburg State Budgetary Health Institution "Children's City Polyclinic No. 45 of the Nevsky District" | Saint Petersburg | |
Russian Federation | St. Petersburg State Budgetary Healthcare Institution City Polyclinic No.106 Children's Polyclinic Department No. 37 | Saint Petersburg | |
Russian Federation | State Budgetary Healthcare Institution of the Samara region "Samara Regional Children's Clinical Hospital named after N.N. Ivanova" | Samara | |
Russian Federation | Limited Liability Company Center DNK-issledovaniy | Saratov | |
Russian Federation | Federal State Budgetary Educational Institution of Higher Education "Tyumen State Medical University" of the Ministry of Healthcare of the Russian Federation | Tyumen |
Lead Sponsor | Collaborator |
---|---|
NPO Petrovax |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To prove non-inferior immunogenicity of the Grippol Quadrivalent vaccine when compared to the Grippol plus vaccine in children aged 6 months to 5 years (inclusive) for three matching strains of the compared vaccines | Proportion of vaccinated seroconverters in paired hemagglutination inhibition test sera obtained before and after vaccination
Seroconversion is defined as: increase in antibody titer to influenza virus strains to = 1:40 (with initial antibody titer < 1:10); or an increase in antibody titer by 4 or more times compared to the initial titer (with an initial antibody titer = 1:10) in paired sera RTGA after vaccination. The initial antibody titer will be the titers of antibodies to influenza virus antigens in the hemagglutination inhibition reaction obtained during screening. Post-vaccination titres will be those obtained on Day 25±3 after a single dose of vaccine in children 36 months to 5 years of age or a second dose of vaccine in children 6 to 35 months of age. |
Baseline to Day 25±3 | |
Secondary | Geometric mean antibody titers | Geometric mean antibody titers after vaccination for three matching strains | Baseline to Day 25±3 | |
Secondary | Proportion of those vaccinated with seroconversion and geometric mean titer | Proportion of those vaccinated with seroconversion and geometric mean titer of antibodies to the fourth additional strain of compared vaccines | Baseline to Day 25±3 | |
Secondary | Multiplicity of the increase in the geometric mean titer | Multiplicity of the increase in the geometric mean titer of antibodies to 4 strains of the influenza virus in paired sera of the hemagglutination inhibition reaction after vaccination in relation to the initial values of antibody titers | Baseline to Day 25±3 | |
Secondary | Seroprotection | Seroprotection (proportion (%) vaccinated with antibody titer = 1:40 to 4 strains of influenza virus in paired sera of the hemagglutination inhibition reaction after vaccination) | Baseline to Day 25±3 | |
Secondary | Incidence of influenza and acute respiratory infections (ARI) | • Incidence of influenza and ARI (Month 1 - Month 6 after vaccination) | Month 1-6 | |
Secondary | The severity and duration of registered cases of influenza and acute respiratory infections (ARI), the presence of complications | The severity and duration of registered cases of influenza and ARI, the presence of complications (Month 1 - Month 6 after vaccination) | Month 1 to Month 6 | |
Secondary | To assess the reactogenicity of the vaccine Grippol Quadrivalent and the vaccine Grippol plus | Frequency and nature of general and local post-vaccination reactions (7-day follow-up period after vaccine administration) | First 7 days after vaccination | |
Secondary | Frequency and nature of SAEs | Frequency and nature of SAEs (Day 1-Month 6) | Baseline to month 6 | |
Secondary | Frequency and nature of medically attended AEs | Frequency and nature of medically attended AEs (Month 1-Month 6) | Baseline to month 6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |